Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]